These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 19086768)
1. Medications for stimulant abuse: agonist-based strategies and preclinical evaluation of the mixed-action D-sub-2 partial agonist aripiprazole (Abilify). Bergman J Exp Clin Psychopharmacol; 2008 Dec; 16(6):475-83. PubMed ID: 19086768 [TBL] [Abstract][Full Text] [Related]
2. Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice. Leite JV; Guimarães FS; Moreira FA Eur J Pharmacol; 2008 Jan; 578(2-3):222-7. PubMed ID: 18021764 [TBL] [Abstract][Full Text] [Related]
3. Aripiprazole as a potential pharmacotherapy for stimulant dependence: human laboratory studies with d-amphetamine. Stoops WW Exp Clin Psychopharmacol; 2006 Nov; 14(4):413-21. PubMed ID: 17115868 [TBL] [Abstract][Full Text] [Related]
4. A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine. Stoops WW; Lile JA; Glaser PE; Rush CR Drug Alcohol Depend; 2006 Sep; 84(2):206-9. PubMed ID: 16540264 [TBL] [Abstract][Full Text] [Related]
5. Discriminative stimulus, subject-rated and cardiovascular effects of cocaine alone and in combination with aripiprazole in humans. Lile JA; Stoops WW; Glaser PE; Hays LR; Rush CR J Psychopharmacol; 2011 Nov; 25(11):1469-79. PubMed ID: 20952456 [TBL] [Abstract][Full Text] [Related]
6. Aripiprazole attenuates the discriminative-stimulus and subject-rated effects of D-amphetamine in humans. Lile JA; Stoops WW; Vansickel AR; Glaser PE; Hays LR; Rush CR Neuropsychopharmacology; 2005 Nov; 30(11):2103-14. PubMed ID: 15988473 [TBL] [Abstract][Full Text] [Related]
7. Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse. Feltenstein MW; Altar CA; See RE Biol Psychiatry; 2007 Mar; 61(5):582-90. PubMed ID: 16806092 [TBL] [Abstract][Full Text] [Related]
8. Aripiprazole and haloperidol suppress excessive dopamine release in the amygdala in response to conditioned fear stress, but show contrasting effects on basal dopamine release in methamphetamine-sensitized rats. Oshibuchi H; Inada K; Sugawara H; Ishigooka J Eur J Pharmacol; 2009 Aug; 615(1-3):83-90. PubMed ID: 19477171 [TBL] [Abstract][Full Text] [Related]
9. Drug discrimination in methamphetamine-trained monkeys: agonist and antagonist effects of dopaminergic drugs. Tidey JW; Bergman J J Pharmacol Exp Ther; 1998 Jun; 285(3):1163-74. PubMed ID: 9618419 [TBL] [Abstract][Full Text] [Related]
10. Modification by dopaminergic drugs of choice behavior under concurrent schedules of intravenous saline and food delivery in monkeys. Gasior M; Paronis CA; Bergman J J Pharmacol Exp Ther; 2004 Jan; 308(1):249-59. PubMed ID: 14563783 [TBL] [Abstract][Full Text] [Related]
11. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release. Aihara K; Shimada J; Miwa T; Tottori K; Burris KD; Yocca FD; Horie M; Kikuchi T Brain Res; 2004 Apr; 1003(1-2):9-17. PubMed ID: 15019558 [TBL] [Abstract][Full Text] [Related]
12. Attenuation of reinforcing and psychomotor stimulant effects of amphetamine by aripiprazole. Bäckström P; Etelälahti TJ; Hyytiä P Addict Biol; 2011 Jan; 16(1):55-63. PubMed ID: 21158016 [TBL] [Abstract][Full Text] [Related]
13. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049 [TBL] [Abstract][Full Text] [Related]
14. Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration. Wee S; Wang Z; Woolverton WL; Pulvirenti L; Koob GF Neuropsychopharmacology; 2007 Oct; 32(10):2238-47. PubMed ID: 17327886 [TBL] [Abstract][Full Text] [Related]
15. Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. Wood MD; Scott C; Clarke K; Westaway J; Davies CH; Reavill C; Hill M; Rourke C; Newson M; Jones DN; Forbes IT; Gribble A Eur J Pharmacol; 2006 Sep; 546(1-3):88-94. PubMed ID: 16925992 [TBL] [Abstract][Full Text] [Related]
16. Aripiprazole, alcohol and substance abuse: a review. Brunetti M; Di Tizio L; Dezi S; Pozzi G; Grandinetti P; Martinotti G Eur Rev Med Pharmacol Sci; 2012 Oct; 16(10):1346-54. PubMed ID: 23104650 [TBL] [Abstract][Full Text] [Related]
17. Cariprazine (RGH-188), a D₃-preferring dopamine D₃/D₂ receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats. Román V; Gyertyán I; Sághy K; Kiss B; Szombathelyi Z Psychopharmacology (Berl); 2013 Mar; 226(2):285-93. PubMed ID: 23138433 [TBL] [Abstract][Full Text] [Related]
18. In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling. Jordan S; Regardie K; Johnson JL; Chen R; Kambayashi J; McQuade R; Kitagawa H; Tadori Y; Kikuchi T J Psychopharmacol; 2007 Aug; 21(6):620-7. PubMed ID: 17092971 [TBL] [Abstract][Full Text] [Related]